Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
40 hedge funds and large institutions have $55.2M invested in Merrimack Pharmaceuticals, Inc. in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 4 closing their positions.
599% more call options, than puts
Call options by funds: $3.31M | Put options by funds: $474K
97% more capital invested
Capital invested by funds: $28M → $55.2M (+$27.2M)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
7.4% more ownership
Funds ownership: 52.25% → 59.65% (+7.4%)
5% more funds holding
Funds holding: 38 → 40 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$1.32M |
| 2 |
NM
Newtyn Management
New York
|
+$1.24M |
| 3 |
Two Sigma Advisers
New York
|
+$1.09M |
| 4 |
Renaissance Technologies
New York
|
+$872K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$432K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$255K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$82.1K |
| 3 |
LA
LVW Advisors
Pittsford,
New York
|
-$80K |
| 4 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$31.1K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$11K |
MACK Hedge Fund Activity: Q4 2020 in Review
40 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2020, worth a combined $55.2M — up 97% from $28M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new MACK positions and 4 closed out — a net gain of 2 holders — while 7 added to existing stakes and 10 trimmed.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $1.32M. The largest seller was Western Standard LLC, cutting an estimated $255K.
- 40 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2020, up from 38 in Q3 2020.
- Funds reported $55.2M of Merrimack Pharmaceuticals, Inc. stock for Q4 2020, up 97% quarter-over-quarter.
- 6 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2020 and 4 closed out, a net change of +2 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2020 was Two Sigma Investments, an estimated $1.32M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2020 was Western Standard LLC, an estimated $255K sold.
Based on aggregated 13F filings for Q4 2020.